Abstract Number: 1562 • ACR Convergence 2025
Vasodilation with Prostanoids Influences Progression of Systemic Sclerosis-Associated Interstitial Lung Disease: a EUSTAR Cohort Study
Background/Purpose: Although most vasoactive vasodilating drugs (VVDs) exert anti-fibrotic effects in pre-clinical studies, randomized controlled trials assessing their efficacy in systemic sclerosis-associated interstitial lung disease…Abstract Number: 0683 • ACR Convergence 2025
Symptom-Based Clustering of Gastrointestinal Involvement in Systemic Sclerosis
Background/Purpose: Virtually all patients with systemic sclerosis (SSc) experience gastrointestinal (GI) manifestations over the course of their disease, affecting any region from the mouth to…Abstract Number: 2472 • ACR Convergence 2025
Digesting the data: tracking gastro-intestinal manifestations in systemic sclerosis over time
Background/Purpose: Gastrointestinal (GI) involvement is among the most frequent organ manifestations in systemic sclerosis (SSc), yet the timing of presentation of GI manifestations remains incompletely…Abstract Number: 1561 • ACR Convergence 2025
Usefulness of HRCT in screening of interstitial lung disease in patients with systemic sclerosis without risk factors of clinical suspicion
Background/Purpose: In 2019 a European expert consensus suggested that all patients with systemic sclerosis (SSc) should be screened with HRCT for interstitial lung disease (ILD)…Abstract Number: 0674 • ACR Convergence 2025
Quantitative Imaging in Systemic Sclerosis Patients Receiving Sodium Thiosulfate for Calcinosis Cutis
Background/Purpose: Calcinosis cutis (CC) is a disabling skin condition associated with systemic sclerosis (SSc). Although many CC treatments including sodium thiosulfate (STS) have been proposed,…Abstract Number: L01 • ACR Convergence 2024
Targeted Exosite Inhibition of STING Activation of TBK1 Selectively Blocks Type I Interferon and NFκB Responses for Treatment of Autoimmune Diseases
Background/Purpose: The cGAS-TBK1-STING pathway senses nucleic acids for innate immunity. Aberrant activation of the pathway is linked to autoimmune diseases including Systemic and Cutaneous Lupus…Abstract Number: 0961 • ACR Convergence 2024
Multi-omics Study of Systemic Sclerosis Immunoglobulins G Effects on Endothelial Cells: A Distinct Profile in Anti-Topoisomerase I Positive Patients
Background/Purpose: Systemic sclerosis (SSc) is a heterogeneous connective tissue disease characterized by autoimmunity, fibrosis and vasculopathy. Antinuclear antibodies (ANA) are strong diagnostic and prognosis biomarkers…Abstract Number: 1976 • ACR Convergence 2024
Artificial Intelligence Analysis of HRCT Images Reflects Pulmonary Involvement in Systemic Sclerosis Interstitial Lung Disease
Background/Purpose: Interstitial lung disease (ILD) is the leading cause of mortality and morbidity in systemic sclerosis (SSc) patients. Current functional, imaging, and clinical measures of…Abstract Number: 2645 • ACR Convergence 2024
Human NCF1-p.R90H Variant Promotes Pulmonary Fibrosis in the Bleomycin-induced Mouse Model and Systemic Sclerosis Patients via Expansion of SPP1+Monocytes-derived Macrophages
Background/Purpose: We previously identified a systemic lupus erythematosus (SLE) causal risk variant, p.Arg90His (p.R90H, rs201802880) substitution encoded in neutrophil cytosolic factor 1 (NCF1), an essential component…Abstract Number: 0967 • ACR Convergence 2024
Transcriptional Heterogeneity of Immune Cells in the Esophagus of Systemic Sclerosis Patients: A Comparison of Upper and Lower Esophageal Regions
Background/Purpose: Systemic sclerosis (SSc) is characterized by an initial inflammatory phase followed by fibrosis. Esophageal dysfunction in SSc is associated with gastroesophageal reflux, leading to…Abstract Number: 2196 • ACR Convergence 2024
Identifying Specific Criteria for Juvenile Systemic Sclerosis: A Comparison of Adult and Pediatric Ratings
Background/Purpose: Despite the high morbidity and mortality risk associated with juvenile systemic sclerosis (jSSc), evidence to guide management is limited. No jSSc clinical trials have…Abstract Number: 2654 • ACR Convergence 2024
Adapting and Testing a Cognitive Rehabilitation Intervention Tailored for People with Systemic Sclerosis: Acceptability, Feasibility, & Impact on Health-related Outcomes
Background/Purpose: Cognitive dysfunction affects up to 87% of individuals with systemic sclerosis (SSc), often significantly impairing their work and daily activities and exacerbating other symptoms…Abstract Number: 1070 • ACR Convergence 2024
Evaluating & Improving Adherence to Pulmonary Hypertension Screening in Systemic Sclerosis Patients
Background/Purpose: Annual screening for pulmonary hypertension (PH) in patients with Systemic Sclerosis (SSc) has been shown to decrease mortality. The American College of Radiology, European…Abstract Number: 2200 • ACR Convergence 2024
Whole Blood Transcriptome Profiling in Juvenile Systemic Sclerosis Patients Reveals Active Immune Upregulation and Enhanced Fibrotic Signature
Background/Purpose: Juvenile systemic sclerosis (jSSc) is a rare chronic autoimmune disorder characterized by skin thickening and multisystem organ involvement, leading to significant morbidity. The pathogenesis…Abstract Number: 2685 • ACR Convergence 2024
Association Between Gastrointestinal Bacterial Species and Radiological Features of Systemic Sclerosis-Interstitial Lung Disease (SSc-ILD): A Multicenter Study from the SSc Microbiome Consortium Project
Background/Purpose: Variations in gastrointestinal (GI) microbial communities may influence the development of lung diseases. Patients with SSc-ILD have a unique intestinal microbial signature. To further…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 16
- Next Page »
